<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25906757</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>06</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1720-8386</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>38</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of endocrinological investigation</Title>
                <ISOAbbreviation>J. Endocrinol. Invest.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>1,25(OH)2D3 downregulates the Toll-like receptor 4-mediated inflammatory pathway and ameliorates liver injury in diabetic rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1083-91</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40618-015-0287-6</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Fatty acid deposition in the liver can activate a number of pro-inflammatory signaling pathways such as the Toll-like receptor 4 (TLR4) pathway, which may be important in the pathogenesis of nonalcoholic steatohepatitis. 1,25(OH)2D3 downregulates the expression of TLR4 and may represent a novel treatment strategy for reducing hepatocyte injury. Therefore, in this study, we investigated the protective effects of 1,25(OH)2D3 on diabetic liver injury in vivo.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Streptozotocin (STZ)-induced diabetic rats were randomly divided into five groups and treated with low-dose 1,25(OH)2D3 (0.025 μg/kg/day), medium-dose 1,25(OH)2D3 (0.15 μg/kg/day), high-dose 1,25(OH)2D3 (0.3 μg/kg/day), insulin (protamine zinc insulin 16 U/kg/day, subcutaneous injection), or no intervention (the control group). Sixteen weeks later, the rats were killed, and blood samples were obtained to test lipid profiles and hepatic function. The infiltration of inflammatory cells, the level of fibrosis, and the expression levels of TLR4, nuclear factor-kappa B (NF-κB), and tumor necrosis factor-α (TNF-α) in the liver were analyzed. The hepatocytes were treated with vehicle control, LPS (100 ng), high fat [DMEM + FFA (0.1 mM: palmitic acid, oleic acid, 1:2)], LPS + high fat, vehicle + 1,25(OH)2D3 (10(-7) M), LPS + 1,25(OH)2D3, high fat + 1,25(OH)2D3, or LPS + high fat + 1,25(OH)2D3. RNA and protein were extracted to detect the expression of TLR4 and downstream inflammatory factors such as NF-ΚB, TNF-α, and IL-6. Groups of data were compared by single factor variance analysis.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">High-dose 1,25(OH)2D3 administration for 16 weeks downregulated the expression of TLR4, NF-κB, and TNF-α in the liver tissue of diabetic rats and attenuated hepatic inflammation and fibrosis, as shown by immunohistochemical staining, hematoxylin and eosin staining, Masson's trichrome staining, reverse transcription polymerase chain reaction (RT-PCR), and western blotting. In vitro, hepatocytes treated with high fat or LPS exhibited significantly increased expression of TLR4, NF-κB, and downstream inflammatory factors (P &lt; 0.05). Intervention with 1,25(OH)2D3 decreased the expression of TLR4, NF-κB, and inflammatory factors (P &lt; 0.05).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">1,25(OH)2D3 exhibited protective effects against diabetes-related liver injury, possibly through downregulation of components of the TLR4 signaling pathway.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Endocrinology, Tianjin Medical University General Hospital, Tianjin, 300052, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Q</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Endocrinology, Tianjin Medical University General Hospital, Tianjin, 300052, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chai</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Endocrinology, Tianjin Medical University General Hospital, Tianjin, 300052, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Endocrinology, Tianjin Medical University General Hospital, Tianjin, 300052, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Endocrinology, Tianjin Medical University General Hospital, Tianjin, 300052, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Endocrinology, Tianjin Medical University General Hospital, Tianjin, 300052, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Endocrinology, Tianjin Medical University General Hospital, Tianjin, 300052, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cui</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Endocrinology, Tianjin Medical University General Hospital, Tianjin, 300052, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qu</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Epidemiology, Human Genetics and Environmental Sciences, University of Texas School of Public Health, Houston, TX, 77030, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Endocrinology, Tianjin Medical University General Hospital, Tianjin, 300052, China. meichuqin@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>04</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Italy</Country>
            <MedlineTA>J Endocrinol Invest</MedlineTA>
            <NlmUniqueID>7806594</NlmUniqueID>
            <ISSNLinking>0391-4097</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1406-16-2</RegistryNumber>
                <NameOfSubstance UI="D014807">Vitamin D</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>66772-14-3</RegistryNumber>
                <NameOfSubstance UI="C097949">1,25-dihydroxyvitamin D</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003921" MajorTopicYN="N">Diabetes Mellitus, Experimental</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D065626" MajorTopicYN="N">Non-alcoholic Fatty Liver Disease</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051197" MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014807" MajorTopicYN="N">Vitamin D</DescriptorName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">1,25(OH)2D3</Keyword>
            <Keyword MajorTopicYN="N">Diabetes</Keyword>
            <Keyword MajorTopicYN="N">Hepatocytes</Keyword>
            <Keyword MajorTopicYN="N">Inflammation</Keyword>
            <Keyword MajorTopicYN="N">Liver injury</Keyword>
            <Keyword MajorTopicYN="N">Toll-like receptor 4</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>01</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>04</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>4</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>4</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>6</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25906757</ArticleId>
            <ArticleId IdType="doi">10.1007/s40618-015-0287-6</ArticleId>
            <ArticleId IdType="pii">10.1007/s40618-015-0287-6</ArticleId>
            <ArticleId IdType="pmc">PMC4768236</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Am J Clin Nutr. 2009 May;89(5):1321-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19321573</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nutr Metab Cardiovasc Dis. 2007 Sep;17(7):517-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16928437</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2011 Nov;54(5):1570-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21793032</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Clin Pathol. 2011 Mar;135(3):429-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21350098</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Lipid Res. 2012 Sep;53(9):2002-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22766885</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocr J. 2013;60(6):743-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23411507</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2011 Aug;55(2):415-25</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21184788</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hepatol. 2013 Aug;59(2):344-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23557869</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Endocrinol Metab. 2008 Feb;93(2):578-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18029454</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Am Coll Cardiol. 1999 Dec;34(7):1975-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10588212</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Leukoc Biol. 2010 Jun;87(6):989-99</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20179153</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Hepatology. 2012 Apr;55(4):1103-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21994008</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Turk J Gastroenterol. 2011 Aug;22(4):400-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21948571</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2275-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18818414</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Endocrine. 2014 Sep;47(1):70-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24968737</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>ARYA Atheroscler. 2014 Mar;10(2):82-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25161675</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Clin Nutr. 2007 Jan;85(1):54-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17209177</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>